Phase i clinical trial of the 131I-Labeled Anticarcinoembryonic Antigen CIGB-M3 Multivalent Antibody Fragment

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 3, 2011, Pages 353-363

  González, Gilmara Pimentel ^a   García, Idrian García ^b   González, Joaquín González ^a   Sánchez, Lincidio Pérez ^b   Mirabal, Milagros Velasco ^a   Marín, Carlos Calderón ^a   Ruiz, Fausto L García ^a   Iglesias, Elizeth Garcia ^b   De Queralta, Rosalina López ^c   Toirac, Ramón Ropero ^a   Ávila, Marta Ayala ^b   Díaz, Adlín López ^c   Saura, Pedro A López ^b   Gavilondo, Jorge V ^b   González, Juan P Oliva ^a  

^a INSTITUTO NACIONAL DE ONCOLOGÍA Y RADIOBIOLOGÍA   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^c HOSPITAL CLINICOQUIRÚRGICO HERMANOS AMEIJEIRAS   (Cuba)

Author keywords

antibody fragment; biodistribution; CEA; colorectal cancer; pharmacokinetics

Indexed keywords

CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CENTER FOR ENGINEERING AND BIOTECHNOLOGY M3 ANTIBODY; IODINE 131; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; COLORECTAL CANCER; CREATININE BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG UPTAKE; DYSURIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; GASTRIC HYPERACIDITY; HEMATURIA; HUMAN; ISOTOPE LABELING; LEUKOCYTOSIS; MALE; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOSIS; VOMITING;

AGED; AGED, 80 AND OVER; ANTIBODIES; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IODINE RADIOISOTOPES; KIDNEY; LIVER; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RADIOMETRY; SINGLE-CHAIN ANTIBODIES; TIME FACTORS;

EID: 79960067100     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2010.0899     Document Type: Article

References (34)

1. Oriuchi N, Higuchi T, Hanaoka H, et al. Current status of cancer therapy with radiolabeled monoclonal antibody. Ann Nucl Med 2005;19:355.
2. Oyen WJG, Bodei L, Giammarile F, et al. Targeted therapy in nuclear medicine-current status and future prospects. Ann Oncol 2007;18:1782.
3. Koppe MJ, Postema EJ, Aarts F, et al. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev 2005;24:539.
4. DeNardo GL, Sysko VV, DeNardo SJ. Cure of incurable lymphoma. Int J Radiat Oncol Biol Phys 2006;66:S46.
5. Macklis RM. Iodine-131 tositumomab (Bexxar) in a radiation oncology environment. Int J Radiat Oncol Biol Phys 2006; 66:S30.
6. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005;46:116s.
7. Chester K, Pedley B, Tolner B, et al. Engineering antibodies for clinical applications in cancer. Tumor Biol 2004;25:91-98. (Pubitemid 38822775)
8. Wu AM, Senter PD. Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23:1137.
9. Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol 2009;27:331.
10. Pérez L, Ayala M, Pimentel G, et al. A multivalent recombinant antibody fragment specific for carcinoembryonic antigen. Biotechnol Appl Biochem 2006;43:39.
11. Goldenberg DM, DeLand F, Kim E, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978;298:1384.
12. Mach JP, Carrel S, Forni M, et al. Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma. N Engl J Med 1980;303:5.
13. Baranov V, Yeung MMW, Hammarstrom S. Expression of carcinoembryonic antigen and nonspecific cross-reacting 50 kDa antigen in human normal and cancerous colon mucosa: Comparative ultrastructural study with monoclonal antibodies. Cancer Res 1994;54:3305.
14. Shi ZR, Tacha D, Itzokowitz H. Monoclonal antibody COL-1 react with restricted epitopes on carcinoembryonic antigen: An immunohistochemical study. J Histochem Cytochem 1994;42:1215.
15. Wu AM, Williams LE, Zieran L, et al. Anticarcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging. Tumor Target 1999;4:47.
16. Foon KA, Yannelli J, Bhattacharya-Chatterjee M. Colorectal cancer as a model for immunotherapy. Clin Cancer Res 1999; 225:225.
17. Pimentel G, Oliva JP, Peralta R, et al. Pharmacokinetics of the Anti-CEA monoclonal antibody: Tc-99m iorCEA.1. World J Nucl Medicine 2004;3:119.
18. Oliva JP, Pimentel G, Velasco M, et al. Radioimmunodetection of colorectal cancer using Tc-99m labeled monoclonal antibody ior-CEA.1: Results of a Phase III clinical trial. World J Nucl Med 2005;4:150.
19. Pimentel G, Ravelo R, Perez L, et al. Diabody construct of ior-CEA.1. Pre-clinical studies for therapeutical application. World J Nucl Med 2007;6:S33.
20. Pérez L, Pimentel G, Ravelo R, et al. Biochemical characterization and tumor targeting properties of an anti-CEA non covalent dimeric recombinant antibody scFv fragment produced in E. coli. Minerva Biotechnol 2008;20:103.
21. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole body dosimetry: Principles and a simplified method for clinical implementation. J Nucl Med 1998;39:14S.
22. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations, revised ed. New York: Society of Nuclear Medicine, 1991;1.
23. Divgi CR. Status of radiolabeled monoclonal antibodies for diagnosis and therapy of cancer. Oncology 1996;10:939.
24. Oliva J, Pimentel G, Cascante L, et al. Radioimmunoscintigraphy of colorrectal tumors with the cuban monoclonal antibody ior-cea 1. Eur J Nucl Med 1998;25(8):1019.
25. Oliva J, Pimentel G, Peralta R, et al. Radioimmunoscintigraphy of colorrectal cancer using the anti-CEA monoclonal antibody BW 431/26. Final results. Rev Esp Med 1999;18:5.
26. Zimmermann R. Nuclear Medicine, Radioactivity for Diagnosis and Therapy. Paris, France: EDP Sciences, 2007.
27. Pizzarello DJ. Direct and indirect action. In: Pizzarello DJ, Witcofski RL (eds.), Basic Radiation Biology. Philadelphia: Lea & Febiger, 1975;20-29.
28. Reynolds JC, Maloney P, Rotman M. Radiohalogenation of monoclonal antibody: Experiences with radioiodination of monoclonal antibodies for radioimmunotherapy. In: Srivastava SC (ed.), Radiolabeled Monoclonal Antibodies for Imaging and Therapy. New York: Plenum, 1988;215.
29. Wahl RL, Wissing J, Rosario RD, et al. Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation. J Nucl Med 1990;31:84.
30. Mann BD, Cohen MB, Saxton RE, et al. Imaging of human tumor xenografts in nude mice with radiolabeled monoclonal antibodies. Limitations of specificity due to nonspecific uptake of antibody. Cancer 1984;54:1318.
31. Thurber GM, Shmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci 2008; 29:57.
32. Jain M, Venkatraman G, Batra SK. Optimization of radioimmunotherapy of solid tumors: Biological impediments and their modulation. Clin Cancer Res 2007; 13:1374.
33. Wong JYC, ChuDZ, Williams LE, et al. Pilot trial evaluating an 123I-Labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66Minibody) in patients with colorectal cancer. Clin Cancer Res 2004;10:5014.
34. Casey JL, Napier MP, King DJ, et al. Tumor targeting of humanized cross-linked divalent-Fab antibody fragments: A clinical phase I/II study. Br J Cancer 2002;86:1401.